1. Market Research
  2. > All Companies
  3. > Wilex AG - Financial and Strategic SWOT Analysis Review

Wilex AG - Financial and Strategic SWOT Analysis Review

  • January 2013
  • -
  • Global Data
  • -
  • 39 pages

Summary

Wilex AG (Wilex) is a oncology focused biopharmaceutical company. It discovers, develops and commercializes diagnostic and therapeutic products in the field of oncology. The therapeutic products developed by the company are based on monoclonal antibodies and small molecules. The diagnostic tests offered by the company are sold through Wilex, Inc., a subsidiary of the company, which is indulged in marketing of ontological biomarker tests, under the brand name Oncogene Science. Its product pipeline comprises Mesupron, is being studied for the treatment of breast cancer; WX-554, for the treatment of solid tumors and WX-037 for the treatment against tumor cell amongst others.

Wilex AGKey Recent Developments

Dec 04, 2012: Wilex AG Announces Restructuring, Reduces Workforce By 25%
Aug 07, 2012: Wilex Appoints Jan Schmidt-Brand As CFO
Jul 12, 2012: Wilex Reports Revenue Of €7.2m In H1 2012
Apr 12, 2012: Wilex Reports Revenue Of €3.7m In Q1 2012
Feb 27, 2012: Wilex Reports Revenue Of €9.9m In 2011

This comprehensive SWOT profile of Wilex AG provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Table Of Contents

Wilex AG - Financial and Strategic SWOT Analysis Review
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Wilex AG - Key Facts 5
Wilex AG - Key Employees 6
Wilex AG - Key Employee Biographies 7
Wilex AG - Major Products and Services 8
Wilex AG - Pharmaceutical Pipeline Products Data 9
Wilex AG, Pipeline Products by Therapy Area 9
Wilex AG, Pipeline Products by Development Phase 10
Wilex AG - History 12
Wilex AG - Company Statement 14
Wilex AG - Locations And Subsidiaries 15
Head Office 15
Other Locations and Subsidiaries 15
Section 2 - Company Analysis 16
Wilex AG - Business Description 16
Wilex AG - Corporate Strategy 18
Wilex AG - SWOT Analysis 19
SWOT Analysis - Overview 19
Wilex AG - Strengths 19
Strength - Sturdy RandD Activities 19
Strength - Broad Patent Portfolio 19
Wilex AG - Weaknesses 19
Weakness - Limited Operating Capability 19
Weakness - Business Shortcomings 20
Wilex AG - Opportunities 20
Opportunity - Strategic Initiatives 20
Opportunity - Strong Product Pipeline 20
Opportunity - Market Potential: Cancer 20
Wilex AG - Threats 21
Threat - Uncertain RandD Outcomes 21
Threat - Stringent Government Regulations 21
Threat - Competition Pressures 21
Wilex AG - Key Competitors 22
Section 3 - Company Financial Ratios 23
Financial Ratios - Capital Market Ratios 23
Financial Ratios - Annual Ratios 23
Performance Chart 25
Financial Performance 25
Financial Ratios - Interim Ratios 26
Financial Ratios - Ratio Charts 27
Section 4 - Company's Lifesciences Financial Deals and Alliances 28
Wilex AG, Pharmaceuticals and Healthcare, Deals By Year, 2007 to YTD 2013 28
Wilex AG, Pharmaceuticals and Healthcare, Deals By Type, 2007 to YTD 2013 29
Wilex AG, Recent Deals Summary 30
Section 5 - Company's Recent Developments 31
Wilex AG, Recent Developments 31
Dec 04, 2012: Wilex AG Announces Restructuring, Reduces Workforce By 25% 31
Aug 07, 2012: Wilex Appoints Jan Schmidt-Brand As CFO 31
Jul 12, 2012: Wilex Reports Revenue Of €7.2m In H1 2012 31
Apr 12, 2012: Wilex Reports Revenue Of €3.7m In Q1 2012 33
Feb 27, 2012: Wilex Reports Revenue Of €9.9m In 2011 34
Section 6 - Appendix 35
Methodology 35
Ratio Definitions 35
About GlobalData 39
Contact Us 39
Disclaimer 39


List of Tables

Wilex AG, Key Facts 5
Wilex AG, Key Employees 6
Wilex AG, Key Employee Biographies 7
Wilex AG, Major Products and Services 8
Wilex AG, Number of Pipeline Products by Therapy Area 9
Wilex AG, Number of Pipeline Products by Development Stage 10
Wilex AG, Pipeline Products By Therapy Area and Development Phase 11
Wilex AG, History 12
Wilex AG, Subsidiaries 15
Wilex AG, Key Competitors 22
Wilex AG, Ratios based on current share price 23
Wilex AG, Annual Ratios 23
Wilex AG, Interim Ratios 26
Wilex AG, Pharmaceuticals and Healthcare, Deals By Year, 2007 to YTD 2013 28
Wilex AG, Pharmaceuticals and Healthcare, Deals By Type, 2007 to YTD 2013 29
Wilex AG, Recent Deals Summary 30
Currency Codes 35
Capital Market Ratios 35
Equity Ratios 36
Profitability Ratios 36
Cost Ratios 37
Liquidity Ratios 37
Leverage Ratios 38
Efficiency Ratios 38


List of Figures

Wilex AG, Pipeline Products by Therapy Area 9
Wilex AG, Pipeline Products by Development Phase 10
Wilex AG, Performance Chart (2007 - 2011) 25
Wilex AG, Ratio Charts 27
Wilex AG, Pharmaceuticals and Healthcare, Deals By Year, 2007 to YTD 2013 28
Wilex AG, Pharmaceuticals and Healthcare, Deals by Type, 2007 to YTD 2013 29

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.